61367-62-2

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 20, p. 299, 1977 DOI: 10.1021/jm00212a022

InChI:InChI=1/C9H11BrO3/c1-12-7-3-6(5-11)4-8(13-2)9(7)10/h3-4,11H,5H2,1-2H3

Upstream product

• 26050-64-6 methyl 4-bromo-3,5-dimethoxybenzoate 
• 705-76-0 3,5-dimethoxybenzyl alcohol 
• 56518-42-4 4-bromo-3,5-dimethoxybenzoic acid 
• 16534-12-6 3,5-dihydroxy-4-bromobenzoic acid 
• 1132-21-4 3,5-dimethoxybenzoic acid 
• 745026-69-1 ethyl 4-bromo-3,5-dimethoxybenzoate 
• 64-17-5 ethanol 
• 99-10-5 3,5-Dihydroxybenzoic acid 

Downstream Products

• 61367-63-3 4-bromo-3,5-dimethoxybenzyl chloride 
• 276880-04-7 2-bromo-1,3-dimethoxy-5-[(1,1-dimethylethyl)diphenylsilyloxymethyl]benzene 
• 500711-36-4 1-[(4-bromo-3,5-dimethoxybenzyl)oxy]tetrahydro-2H-pyran 
• 914933-64-5 1-[4-(tert-butyl-dimethyl-silanyloxymethyl)-2,6-dimethoxy-phenyl]-2-(2-methyl-[1,3]dioxolan-2-yl)-ethanol 
• 914933-62-3 2-bromo-3,5-dimethoxy-4-[2-(2-methyl-[1,3]dioxolan-2-yl)-1-triisopropylsilanyloxy-ethyl]-benzaldehyde 
• 914933-67-8 {2-bromo-3,5-dimethoxy-4-[2-(2-methyl-[1,3]dioxolan-2-yl)-1-triisopropylsilanyloxy-ethyl]-phenyl}-methanol 
• 914933-65-6 2-{2-[4-(tert-butyl-dimethyl-silanyloxymethyl)-2,6-dimethoxy-phenyl]-2-triisopropylsilanyloxy-ethyl}-2-methyl-[1,3]dioxolane 
• 914933-66-7 2-{2-[3-bromo-4-(tert-butyl-dimethyl-silanyloxymethyl)-2,6-dimethoxy-phenyl]-2-triisopropylsilanyloxy-ethyl}-2-methyl-[1,3]dioxolane 
• 276880-05-8 2,6-dimethoxy-4-[(1,1-dimethylethyl)diphenylsilyloxymethyl]benzaldehyde 
• 276880-06-9 1-{4-[(1,1-dimethylethyl)diphenylsilyloxymethyl]-2,6-dimethoxyphenyl}pent-1-en-3-one 
• 276880-07-0 rac-1-{4-[(1,1-dimethylethyl)diphenylsilyloxymethyl]-2,6-dimethoxyphenyl}pent-1-en-3-ol 
• 276880-20-7 (7S)-methyl 2-(dimethoxyphosphoryl)-7-(4-formyl-2,6-dimethoxyphenyl)undecanoate 
• 276880-21-8 (4E,7S)-methyl 2-(dimethoxyphosphoryl)-7-(4-formyl-2,6-dimethoxyphenyl)undec-4-enoate 
• 276880-19-4 (7S)-methyl 2-(dimethoxyphosphoryl)-7-(4-hydroxymethyl-2,6-dimethoxyphenyl)undecanoate 

Relevant academic research and scientific papers

Xylochemical synthesis and biological evaluation of shancigusin c and bletistrin g

The biological activities of shancigusin C (1) and bletistrin G (2), natural products isolated from orchids, are reported along with their first total syntheses. The total synthesis of shancigusin C (1) was conducted by employing the Perkin reaction to forge the central stilbene core, whereas the synthesis of bletistrin G (2) was achieved by the Wittig olefination followed by several regiose-lective aromatic substitution reactions. Both syntheses were completed by applying only renewable starting materials according to the principles of xylochemistry. The cytotoxic properties of shancigusin C (1) and bletistrin G (2) against tumor cells suggest suitability as a starting point for further structural variation.

Yicathins B and C and Analogues: Total Synthesis, Lipophilicity and Biological Activities

Natural products have always been an important source of new hits and leads in drug discovery, with the marine environment being regarded as a significant source of novel and exquisite bioactive compounds. Yicathins B and C are two marine-derived xanthones that have shown antibacterial and antifungal activity. Herein, the total synthesis of these yicathins and six novel analogues is reported for the first time. As marine natural products tend to have very lipophilic scaffolds, the lipophilicity of yicathins and their analogues was evaluated in the classical octanol/water system and a biomimetic model-based system. As the xanthonic nucleus is a “privileged structure”, other biological activities were evaluated, namely antitumor and anti-inflammatory activities. An interesting anti-inflammatory activity was identified for yicathin analogues that paves the way for the design of dual activity (anti-infective and anti-inflammatory) marine-inspired xanthone derivatives.

Chain substituted cannabilactones with selectivity for the CB2 cannabinoid receptor

In earlier work, we reported a novel class of CB2 selective ligands namely cannabilactones. These compounds carry a dimethylheptyl substituent at C3, which is typical for synthetic cannabinoids. In the current study with the focus on the pharmacophoric side chain at C3 we explored the effect of replacing the C1′-gem-dimethyl group with the bulkier cyclopentyl ring, and, we also probed the chain's length and terminal carbon substitution with bromo or cyano groups. One of the analogs synthesized namely 6-[1-(1,9-dihydroxy-6-oxo-6H-benzo[c]chromen-3-yl) cyclopentyl] hexanenitrile (AM4346) has very high affinity (Ki = 4.9 nM) for the mouse CB2 receptor (mCB2) and 131-fold selectivity for that target over the rat CB1 (rCB1). The species difference in the affinities of AM4346 between the mouse (m) and the human (h) CB2 receptors is reduced when compared to our first-generation cannabilactones. In the cyclase assay, our lead compound was found to be a highly potent and efficacious hCB2 receptor agonist (EC50 = 3.7 ± 1.5 nM, E(max) = 89%). We have also extended our structure-activity relationship (SAR) studies to include biphenyl synthetic intermediates that mimic the structure of the phytocannabinoid cannabinodiol.

INTEGRIN ANTAGONISTS

The present disclosure provides therapeutic agents including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such therapeutic agents. Methods of using the therapeutic agents are also provided.

SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF

PROBLEM TO BE SOLVED: To provide novel compounds having excellent α4 integrin inhibitory action. SOLUTION: The invention relates to sulfonamide derivatives represented by the general formula (I) in the figure, or pharmaceutically acceptable salts thereof, or prodrugs thereof. (In the formula, a, b, c, d, D, E, R11, B, e, f, g, h and W are as defined herein.) SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT

Total synthesis of (±)-kuwanol e

The total synthesis of the Diels-Alder-type adducts (±)-kuwanol E and the heptamethyl ether derivative of (±)-kuwanon Y has been accomplished via a convergent strategy involving 2′-hydroxychalcone 6 or 9 and dehydroprenylstilbene 7, in nine steps. The syn

Aryl-Allene Cyclization via a Hg(OTf)2-Catalytic Pathway

Hg(OTf)2-catalyzed aryl-allene cyclization accompanied by formation of a quaternary carbon center has been realized. Deuterium-labeling experiments and computational modeling were used to propose a novel catalytic pathway involving direct H-transfer from the aromatic ring to the vinyl mercury moiety followed by mercury 1,2-migration.

Total synthesis of achlisocoumarins I-II from Achlys triphylla

A concise and efficient total synthesis of achlisocoumarin I-II has been completed featuring a construction of the isocoumarin skeleton in a single step and the geranyl coupling with bromoarene ring at -10 C exclusive of any chelating ligand.

Concise total synthesis of permethylated anigopreissin a, a new benzofuryl resveratrol dimer

The versatile preparation of permethylated anigopreissin A (1) has been accomplished from methyl 3,5-dihydroxybenzoate. The key steps of the synthesis are sequential Sonogashira and Suzuki cross-couplings for the construction of the 2,3-diarylbenzo[b]furan moiety and Wittig olefination for the introduction of the styryl group.

PYRAZOLOTHIAZOLE COMPOUND

A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; R1 is -A11-A12; A11 is a single bond or a C1-6 alkylene group; A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R2 is -A21-A22; A21 is a single bond or a C1-6 alkylene group; A22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R3 is a C 1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R4 is a hydrogen atom or a C1-6 alkoxy group; R5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and R7 is a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group